Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2024 08:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party,...